New way to deliver chemo directly to brain tumors tested in small study
NCT ID NCT05773326
First seen May 17, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This early-phase trial tested a single dose of the cancer drug temsirolimus, given directly into the brain's blood supply, for people with recurrent high-grade glioma (a fast-growing brain tumor). Only 5 participants were enrolled, and the study was terminated early. The main goal was to measure how much drug reaches the tumor tissue, not to determine if it works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temsirolimus (a cancer drug given directly into the brain's blood supply)
What this could lead to
If it works, this could point toward a more targeted way to deliver chemotherapy for aggressive brain tumors.
What could go wrong
This is a very early, tiny trial (only 5 people) that was terminated early. It only tests drug levels, not whether the drug actually helps patients live longer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.